Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
June 04 2018 - 4:05PM
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led
biopharmaceutical company focused on identifying, developing, and
commercializing innovative and differentiated therapies to address
significant unmet needs in medical and aesthetic dermatology, today
announced that on June 1, 2018 the Compensation Committee of
Aclaris’ Board of Directors granted 3 restricted stock unit awards
covering an aggregate of 7,100 shares of its common stock to 3 new
employees under the Aclaris 2017 Inducement Plan. The
restricted stock units were granted as inducements material to the
new employees becoming employees of Aclaris in accordance with
NASDAQ Listing Rule 5635(c)(4).
The 2017 Inducement Plan is used exclusively for the grant of
equity awards to individuals who were not previously an employee or
non-employee director of Aclaris (or following a bona fide period
of non-employment), as an inducement material to such individuals
entering into employment with Aclaris, pursuant to Rule 5635(c)(4)
of the NASDAQ Listing Rules.
Each restricted stock unit award will vest, and become
exercisable (as applicable), as to twenty-five percent of the
shares on each of the first, second, third, and fourth
anniversaries of the recipient's start date, subject to each such
employee's continued employment with Aclaris on such vesting dates.
The restricted stock unit award is subject to the terms and
conditions of Aclaris' 2017 Inducement Plan, and the terms and
conditions of a restricted stock unit agreement, as applicable,
covering the grant.
About Aclaris Therapeutics, Inc.Aclaris
Therapeutics, Inc. is a dermatologist-led biopharmaceutical company
committed to identifying, developing, and commercializing
innovative therapies to address significant unmet needs in
dermatology, both aesthetic and medical, and immunology. Aclaris’
focus on market segments with no FDA-approved medications or where
treatment gaps exist has resulted in the first FDA-approved
treatment for raised seborrheic keratoses and several clinical
programs to develop medications for the potential treatment of
common warts, alopecia areata, and vitiligo. For additional
information, please visit www.aclaristx.com and follow Aclaris on
LinkedIn.
Aclaris ContactMichael Tung, M.D.Senior Vice President Corporate
Strategy/Investor Relations484-329-2140mtung@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jul 2023 to Jul 2024